Completed PHASE4 INTERVENTIONAL 3-arm NCT00532168

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl (ADVANZ-3)

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study.

Sponsor: Juan A. Arnaiz

Conditions HIV Infections

Interventions tenofovir + emtricitabine + atazanavir-ritonavir tenofovir + emtricitabine + efavirenz tenofovir + emtricitabine + lopinavir-ritonavir

Updated 5 times since 2017 Last updated: Feb 21, 2013 Started: Sep 30, 2007 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on HIV Infections, this trial is completed. The trial is conducted by Juan A. Arnaiz and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Juan A. Arnaiz

Data source: Hospital Clinic of Barcelona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain